Fidelity Investments’s Stoke Therapeutics STOK Stock Holding History
Bought
Maintained
Sold
Other funds holding STOK
LCM
Fidelity Investments's STOK Position: Q3 2026 in Review
Fidelity Investments reduced its Stoke Therapeutics (STOK) stake by 5.9% in Q3 2026, selling an estimated $9.43M and leaving 5,000,952 shares worth $130M. The position accounts for 0.01% of the portfolio, ranked #1105.
Fidelity Investments first reported a position in STOK in Q2 2019 and has held it in 30 quarters since. The position peaked at $223M in Q4 2020. 185 funds tracked by Wall St. Rank hold STOK as of Q3 2026.
- Fidelity Investments held 5,000,952 shares of Stoke Therapeutics worth $130M as of Q3 2026.
- Fidelity Investments sold 312,148 Stoke Therapeutics shares in Q3 2026, an estimated $9.43M.
- Stoke Therapeutics made up 0.01% of Fidelity Investments's portfolio in Q3 2026, its #1105 holding.
- Fidelity Investments first reported a position in Stoke Therapeutics in Q2 2019 and has held it in 30 quarters since.
- Fidelity Investments's Stoke Therapeutics position peaked at $223M in Q4 2020.
- 185 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q3 2026.
Based on Fidelity Investments's 13F filing for Q3 2026, filed 10 Nov 2026.